

Express Mail N . EV1395016 US
Date of Deposit: November 8, 2002

RECEIVED

NOV 14 2002

Page 1 of 1

Please type a
plus sign (+)
in this box



TECH CENTER 1600/2900

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Model Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/036,768
Filing Date	November 6, 2001
First Named Inventor	Fast
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	18242-511 (VI-11)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
<i>R</i>	C24	Brown, et al. (1998). "A Universal Inactivant for Decontaminating Blood and Biopharmaceutical Products" <i>Biologicals</i> 26: 39-47.
<i>R</i>	C25	Burrage, et al. (1999). "Inactivation of Viruses by Aziridines" Brown F, Vyas G (eds). <i>Advances in Transfusion Safety. Dev Biol. Basel, Karger</i> 102: 131-139.
<i>R</i>	C26	Yamamoto, Nobuto (1966). "Mechanism of Inactivation of DNA and RNA Bacteriophages by Alkylating Agents In Vitro" <i>Cancer Research</i> 26 (part 1): 2301-2306.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	9/5/03
-----------------------	--	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1730575v1

RECEIVED

OCT 25 2002

TECH CENTER 1600/2900

Please type a
plus sign (+)
in this box

+

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Model Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/036,768
Filing Date	November 6, 2001
First Named Inventor	Fast
Group Art Unit	1614
Examiner Name	Not Yet Assigned
Attorney Docket Number	18242-511 (VI-11)

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
/	A1	3,636,196	1/18/72	Bauer et al.	/	/	
/	A2	4,429,045	1/31/84	Bass et al.	/	/	
/	A3	4,567,042	1/28/86	Acree et al	/	/	
/	A4	5,547,576	8/20/96	Onishi et al	/	/	
/	A5	5,891,705	4/6/99	Budowsky et al	/	/	
/	A6	6,093,564	7/25/00	Budowsky et al	/	/	
/	A7	6,114,108	9/5/00	Budowsky	/	/	
/	A8	6,136,586	10/24/00	Budowsky	/	/	
/	A9	6,150,109	11/21/00	Edson et al	/	/	
/	A10	6,258,357 B1	7/10/01	Spaner	/	/	
/	A11	6,352,695 B1	3/5/02	Budowsky et al.	/	/	
/	A12	6,369,048 B1	4/9/02	Budowsky et al	/	/	
/	A13	6,403,359 B1	6/11/02	Purm al et al.	/	/	
/	A14	6,410,219 B1	1/25/02	Cook et al.	/	/	

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
/	A15	20020123030	9/5/02	Purm al et al.	/	/	

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
/	B1	EP 0 419 890	American Cyanamid Co.	4/3/91		
/	B2	WO 96/39820	Cerus Corporation	12/19/96		
/	B3	WO 97/07674	Pentose Pharmaceuticals, Inc.	3/6/97		
/	B4	WO 98/45415	Pentose Pharmaceuticals, Inc.	10/15/98		
/	B5	WO 99/03976	Cerus Corporation	1/28/99		
/	B6	WO 99/17802	Pentose Pharmaceuticals, Inc.	4/15/99		
/	B7	WO 99/26639	Allegheny University of the Health Sciences	6/3/99		
/	B8	WO 99/34791	Pentose Pharmaceuticals, Inc.	7/15/99		
/	B9	WO 99/63981	Cerus Corporation	12/16/99		
/	B10	WO 00/18412	Pentose Pharmaceuticals, Inc.	4/6/00		


RECEIVED

Express Mail No. EV139500654US

Date of Deposit: October 22, 2002

OCT 25 2002

Page 2 of 1



FOREIGN PATENT DOCUMENTS

TECH CENTER 1600/2900

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B11	WO 00/18969	Pentose Pharmaceuticals, Inc.	4/6/00		
	B12	WO 00/43549	V.I. Technologies, Inc.	7/27/00		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Richter et al. (1998). "Extracorporeal photopheresis in therapy-refractory disseminated discoid lupus erythematosus!" <i>Hautarzt</i> 49(6): 487-491.
	C2	Chapman (2000). "Progress in improving the pathogen safety of red cell concentrates" <i>Vox Sang</i> 78(2): 203-204.
	C3	Fast et al. (2000). "Treatment of human leukocytes with inactine™ results in loss of function and induction of apoptosis" <i>Blood</i> 96(11): 61A
	C4	Lobastov, A.E., (1983) "Use of ethylenimine dimer for the inactivation of infectious rhinotracheitis virus of cattle" <i>Probl. Virusol., Mol. Biol. Gistol. S-kh Zhivotn.</i> , 4-6.
	C5	Amor, S. and H.E. Webb, "Use of N-Acetyethylethimine [AEI] for the activation of Semliki Forest Virus in vitro" <i>J. Medical Virology</i> 19:367-376.
	C6	Zalesskaya, M.A., "Inactivation of viral genome by beta-propiolactone and ethyleneimines using the bacteriophage MA-2 as an example", <i>Russian State Library, Moscow, Russia</i> (1991)
	C7	Budowsky, E.I., "Problems and prospects for preparation of killed antiviral vaccines" <i>Ad. Virus Res.</i> 39:255-90
	C8	Hassanain, M.M., "Preliminary findings for an inactivated African horsesickness vaccine using binary ethylenimine" <i>Revue Elev. Med. Vet. Pays Trop.</i> 45:231-234
	C9	Russian Patent: SU 1809836 A3
	C10	Budowsky, et al. "Inactivation of the phage MS2 infectivity by the Action of Ethyleneimines" <i>Biorg. Khim.</i> 11:989-991 (1985)
	C11	Budowsky, et al "Principles of selective inactivation of the viral genome; dependence of the rate of viral RNA modification on the number of protonizable groups on ethyleneimine Oligomers" <i>Vaccine Res.</i> 5:29-39
	C12	Abstract No. S137-040, AABB Meeting, held in San Antonio, TX, Oct. 13-17, 2001 "Pen 110 Treatment is More Effective than Conventional Gamma Irradiation at Inhibiting Human Peripheral Blood Mononuclear Cell Function: In Vitro Studies".
	C13	Abstract No. SP 185, AABB Meeting, held in San Antonio, TX, Oct. 13-17, 2001 "Removal of White Blood Cell and Plasma Proteins from Leukofiltered Red Blood Cell Concentrates by INACTINE™ Pathogen Inactivation"
	C14	Seghatchian, M.J. et al. Abstract: "Transfusion-associated graft-versus-host disease: current concepts and future trends" <i>Transfus Sci</i> 1995, Jun; 16(2): 99-105.
	C15	Fast, L.D. Abstract: "Recipient CD8+ cells are responsible for the rapid elimination of allogeneic donor lymphoid cells" <i>J Immunol</i> 1996 Dec 1; 157(11):4805-10.
	C16	Fast, L.D. et al. Abstract: "Immune responses to major histocompatibility complex homozygous lymphoid cells in murine F1 hybrid recipients: implications for transfusion-associated graft-versus-host disease" <i>Blood</i> 1995 Oct 15;86(8):3090-6.
	C17	Fast, L.D. "In Vitro Characterization of a Murine Recipient Anti-Donor Effector Cell Responsible for the Development of Chronic Graft-Versus-Host Disease" <i>The Journal of Immunology</i> , Vol. 147, 1731-38. September 15, 1991.
	C18	Fast, L.D. "Recipient Elimination of Allogeneic Lymphoid Cells: donor CD4+ cells are effective alloantigen-presenting cells" <i>Blood</i> , 1 Aug 2000, pp 1144-49, Vol. 96, No. 3.
	C19	Grass, J.A. et al. "Prevention of transfusion-associated graft-versus-host disease by photochemical treatment" <i>Blood</i> 1999 May 1; 93(9):3140-7.


OCT 25 2002

Express Mail N . EV139500654US

Date of Deposit: October 22, 2002

Page 3 of 1

TECH CENTER 1600/2900



OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C20	Yasuda, H et al. Abstract: <i>Mechanism of Transfusion-associated graft-versus host disease</i> " Fukushima J. Med. Sci 1993 Dec; 39(2): 69-75.
	C21	Tsvetkova, E.A. et al. " <i>Principles of Selective Inactivation of a Viral Genome. Comparative Kinetic Study of Modification of the Vira RNA and Model Protein with Oligoaziridines</i> " Biochemistry (Moscow), Vol. 66. No. 8 pp. 875-884. Translated from Biokhimiya, Vol. 66 No. 8, 2001 pp. 1078-1088.
	C22	Kasermann, F. et al. " <i>Virus Inactivation and Protein Modifications by Ethyleneimines</i> " Antiviral Research 52 (2001) pp. 33-41.
	C23	International Search Report for PCT/US 01/49956. Mailed on July 23, 2002.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	9/5/03
-----------------------	--	--------------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1714604v1